Telmisartan ramipril combination therapy reduces strokes and improves cardiac and renal protection in stroke prone spontaneously hypertensive rats

Journal of the American Society of Hypertension

Volumn 1, Issue 6, 2007, Pages 423-432

  Zhou, Ying ^a   Yu, Fangmin ^a   Ene, Ada R ^a   Catanzaro, Daniel F ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

angiotensin receptor blocker; angiotensin converting enzyme inhibitor; Combination therapy; spontaneously hypertensive stroke prone rats; target organ damage

Indexed keywords

COLLAGEN; RAMIPRIL; TELMISARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE REGULATION; BRAIN PROTECTION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; HEART DISEASE; HEART LEFT VENTRICLE; HEART PROTECTION; HYPERTENSION; KIDNEY DISEASE; MONOTHERAPY; NONHUMAN; PRIMARY PREVENTION; PRIORITY JOURNAL; PROTEIN URINE LEVEL; RAT; RENAL PROTECTION; SALT INTAKE; STROKE; STROKE PRONE SPONTANEOUSLY HYPERTENSIVE RAT;

EID: 36549070628     PISSN: 19331711     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jash.2007.08.002     Document Type: Article

References (38)

1. Rocha R., Chander P.N., Zuckerman A., and Stier Jr. C.T. Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension 33 (1999) 232-237
2. Stier C.T.J., Chander P., Gutstein W.H., Levine S., and Itskovitz H.D. Therapeutic benefit of captopril in salt-loaded stroke-prone spontaneously hypertensive rats is independent of hypertensive effect. Am J Hypertens 4 (1991) 680-687
3. von Lutterotti N., Camargo M.J.F., Campbell Jr. W.G., Mueller F.B., Timmermans P.B.M.W.M., Sealey J.E., et al. Angiotensin II receptor antagonist delays renal damage and stroke in salt-loaded Dahl salt-sensitive rats. J Hypertens 10 (1992) 949-957
4. Camargo M.J., von Lutterotti N., Campbell Jr. W.G., Pecker M.S., James G.D., Timmermans P.B., et al. Control of blood pressure and end-organ damage in maturing salt-loaded stroke-prone spontaneously hypertensive rats by oral angiotensin II receptor blockade. J Hypertens 11 (1993) 31-40
5. Barone F., Coatney R., Chandra S., Sarkar S., Nelson A., Contino L., et al. Eprosartan reduces cardiac hypertrophy, protects heart and kidney, and prevents early mortality in severely hypertensive stroke-prone rats. Cardiovasc Res 50 (2001) 525-537
6. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program. JAMA 265 (1991) 3255-3264
7. Biollaz J., Brunner H.R., Gavras I., Waeber B., and Gavras H. Antihypertensive therapy with MK 421: angiotensin II-renin relationships to evaluate efficacy of converting enzyme blockade. J Cardiovasc Pharmacol 4 (1982) 966-972
8. Hornig B., Kohler C., and Drexler H. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation 95 (1997) 1115-1118
9. Azizi M., Guyene T.T., Chatellier G., Wargon M., and Menard J. Additive effects of losartan and enalapril on blood pressure and plasma active renin. Hypertension 29 (1997) 634-640
10. Mogensen C.E., Neldam S., Tikkanen I., Oren S., Viskoper R., Watts R.W., et al. Randomized controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the CAndesartan and Lisinopril Microalbuminuria (CALM) Study. BMJ 321 (2000) 1440-1444
11. Ruilope L., Aldigier J., Ponticelli C., Oddou-Stock P., Botteri F., and Mann J. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease. J Hypertens 18 (2000) 89-95
12. Rossing K., Jacobsen P., Pietraszek L., and Parving H. Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial. Diabetes Care 26 (2003) 2268-2274
13. Russo D., Minutolo R., Pisani A., Esposito R., Signoriello G., Andreucci M., et al. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis 38 (2001) 18-25
14. Nakao N., Yoshimura A., Morita H., Takada M., Kayano T., and Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomized controlled trial. Lancet 361 (2003) 117-124
15. Ferrari P., Marti H., Pfister M., and Frey F. Additive antiproteinuric effect of combined ACE inhibition and angiotensin II receptor blockade. J Hypertens 20 (2002) 125-130
16. Laverman G.D., Navis G., Henning R.H., de Jong P.E., and de Zeeuw D. Dual renin-angiotensin system blockade at optimal doses for proteinuria. Kidney Int 62 (2002) 1020-1025
17. Young J.B., Dunlap M.E., Pfeffer M.A., Probstfield J.L., Cohen-Solal A., Dietz R., et al. Mortality and morbidity reduction with candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation 110 (2004) 2618-2626
18. McMurray J.J., Ostergren J., Swedberg K., Granger C.B., Held P., Michelson E.L., et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 362 (2003) 767-771
19. Anan F., Takahashi N., Ooie T., Yufu K., Hara M., Nakagawa M., et al. Effects of valsartan and perindopril combination therapy on left ventricular hypertrophy and aortic arterial stiffness in patients with essential hypertension. Eur J Clin Pharmacol 61 (2005) 353-359
20. Camargo M.J.F., von Lutterotti N., Campbell Jr. W.G., Pecker M.S., James G.D., Timmermans P.B.M.W.M., et al. Control of blood pressure and end-organ damage in maturing salt-loaded stroke-prone spontaneously hypertensive rats by oral angiotensin II receptor blockade. J. Hypertens 11 (1993) 31-40
21. Richer-Giudicelli C., Domergue V., Gonzalez M.F., Messadi E., Azizi M., Giudicelli J.F., et al. Hemodynamic effects of dual blockade of the renin-angiotensin system in spontaneously hypertensive rats: influence of salt. J Hypertens 22 (2004) 619-627
22. Menard J., Campbell D.J., Azizi M., and Gonzales M.F. Synergistic effects of ACE inhibition and Ang II antagonism on blood pressure, cardiac weight, and renin in spontaneously hypertensive rats. Circulation 96 (1997) 3072-3078
23. Kim S., Zhan Y., Izumi Y., and Iwao H. Cardiovascular effects of combination of perindopril, candesartan, and amlodipine in hypertensive rats. Hypertension 35 (2000) 769-774
24. Morgan T., Griffiths C., and Delbridge L. Low doses of angiotensin converting enzyme inhibitors and angiotensin type 1 blockers have a synergistic effect but high doses are less than additive. Am J Hypertens 15 (2002) 1003-1005
25. Morgan T., Griffiths C., and Delbridge L. Interaction of ACE inhibitors and AT(1)-receptor blockers on maximum blood pressure response in spontaneous hypertensive rats. J Renin Angiotensin Aldosterone Syst 3 (2002) 16-18
26. Naelten G., Liu K.L., Chapuis B., and Lo M. Persistent effects on blood pressure and renal function of perindopril alone or combined with losartan in Lyon hypertensive rats. Am J Hypertens 18 (2005) 699-706
27. Hu L., Sealey J., Chen R., Zhou Y., Merali C., Shi Y., et al. Nitric oxide synthase inhibition accelerates the pressor response to low-dose angiotensin II, exacerbates target organ damage, and induces renin escape. Am J Hypertens 17 (2004) 395-403
28. Griffin K.A., Abu-Amarah I., Picken M., and Bidani A.K. Renoprotection by ACE inhibition or aldosterone blockade is blood pressure-dependent. Hypertension 41 (2003) 201-206
29. Culman J., von Heyer C., Piepenburg B., Rascher W., and Unger T. Effects of systemic treatment with irbesartan and losartan on central responses to angiotensin II in conscious, normotensive rats. Eur J Pharmacol 367 (1999) 255-265
30. Gohlke P., Weiss S., Jansen A., Wienen W., Stangier J., Rascher W., et al. AT1 receptor antagonist telmisartan administered peripherally inhibits central responses to angiotensin II in conscious rats. J Pharmacol Exp Ther 298 (2001) 62-70
31. Liebetrau M., Burggraf D., Wunderlich N., Jager G., Linz W., and Hamann G.F. ACE inhibition reduces activity of the plasminogen/plasmin and MMP systems in the brain of spontaneous hypertensive stroke-prone rats. Neurosci Lett 376 (2005) 205-209
32. Gohlke P., Scholkens B., Henning R., Urbach H., and Unger T. Inhibition of converting enzyme in brain tissue and cerebrospinal fluid of rats following chronic oral treatment with the converting enzyme inhibitors ramipril and Hoe 288. J Cardiovasc Pharmacol 14 (1989) S32-S36
33. Stier C.T.J., Benter I.F., Ahmad S., Zuo H.L., Selig N., Roethel S., et al. Enalapril prevents stroke and kidney dysfunction in salt-loaded stroke-prone spontaneously hypertensive rats. Hypertension 13 (1989) 115-121
34. Chung O., and Unger T. Angiotensin II receptor blockade and end-organ protection. Am J Hypertens 12 (1999) S150-S156
35. van den Eijnden M.M., de Bruin R.J., de Wit E., Sluiter W., Deinum J., Reudelhuber T.L., et al. Transendothelial transport of renin-angiotensin system components. J Hypertens 20 (2002) 2029-2037
36. Rose J.M., and Audus K.L. AT1 receptors mediate angiotensin II uptake and transport by bovine brain microvessel endothelial cells in primary culture. J Cardiovasc Pharmacol 33 (1999) 30-35
37. Tschope C., Schultheiss H.P., and Walther T. Multiple interactions between the renin-angiotensin and the kallikrein-kinin systems: role of ACE inhibition and AT1 receptor blockade. J Cardiovasc Pharmacol 39 (2002) 478-487
38. Kurtz T.W. New treatment strategies for patients with hypertension and insulin resistance. Am J Med 119 (2006) S24-S30